<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39325432</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2046-4924</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>25</Day></PubDate></JournalIssue><Title>Health technology assessment (Winchester, England)</Title><ISOAbbreviation>Health Technol Assess</ISOAbbreviation></Journal><ArticleTitle>Cost-effectiveness of bioimpedance-guided fluid management in patients undergoing haemodialysis: the BISTRO RCT.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>45</EndPage><MedlinePgn>1-45</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3310/JYPR4287</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The BioImpedance Spectroscopy to maintain Renal Output randomised controlled trial investigated the effect of bioimpedance spectroscopy added to a standardised fluid management protocol on the risk of anuria and preservation of residual kidney function (primary trial outcomes) in incident haemodialysis patients. Despite the economic burden of kidney disease, the cost-effectiveness of using bioimpedance measurements to guide fluid management in haemodialysis is not known.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">To assess the cost-effectiveness of bioimpedance-guided fluid management against current fluid management without bioimpedance.</AbstractText><AbstractText Label="DESIGN" NlmCategory="UNASSIGNED">Within-trial economic evaluation (cost-utility analysis) carried out alongside the open-label, multicentre BioImpedance Spectroscopy to maintain Renal Output randomised controlled trial.</AbstractText><AbstractText Label="SETTING" NlmCategory="UNASSIGNED">Thirty-four United Kingdom outpatient haemodialysis centres, both main and satellite units, and their associated inpatient hospitals.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="UNASSIGNED">Four hundred and thirty-nine adult haemodialysis patients with &gt; 500 ml urine/day or residual glomerular filtration rate &gt; 3 ml/minute/1.73 m<sup>2</sup>.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="UNASSIGNED">The study intervention was the incorporation of bioimpedance technology-derived information about body composition into the clinical assessment of fluid status in patients with residual kidney function undergoing haemodialysis. Bioimpedance measurements were used in conjunction with usual clinical judgement to set a target weight that would avoid excessive fluid depletion at the end of a dialysis session.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="UNASSIGNED">The primary outcome measure of the BioImpedance Spectroscopy to maintain Renal Output economic evaluation was incremental cost per additional quality-adjusted life-year gained over 24 months following randomisation. In the main (base-case) analysis, this was calculated from the perspective of the National Health Service and Personal Social Services. Sensitivity analyses explored the impact of different scenarios, sources of resource use data and value sets.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The bioimpedance-guided fluid management group was associated with £382 lower average cost per patient (95% CI -£3319 to £2556) and 0.043 more quality-adjusted life-years (95% CI -0.019 to 0.105) compared with the current fluid management group, with neither values being statistically significant. The probability of bioimpedance-guided fluid management being cost-effective was 76% and 83% at commonly cited willingness-to-pay threshold of £20,000 and £30,000 per quality-adjusted life-year gained, respectively. The results remained robust to a series of sensitivity analyses.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="UNASSIGNED">The missing data level was high for some resource use categories collected through case report forms, due to COVID-19 disruptions and a significant dropout rate in the informing BioImpedance Spectroscopy to maintain Renal Output trial.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Compared with current fluid management, bioimpedance-guided fluid management produced a marginal reduction in costs and a small improvement in quality-adjusted life-years. Results from both the base-case and sensitivity analyses suggested that use of bioimpedance is likely to be cost-effective.</AbstractText><AbstractText Label="FUTURE WORK" NlmCategory="UNASSIGNED">Future work exploring the association between primary outcomes and longer-term survival would be useful. Should an important link be established, and relevant evidence becomes available, it would be informative to determine whether and how this might affect longer-term costs and benefits associated with bioimpedance-guided fluid management.</AbstractText><AbstractText Label="FUNDING DETAILS" NlmCategory="UNASSIGNED">This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number HTA 14/216/01 (NIHR136142).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zanganeh</LastName><ForeName>Mandana</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3934-6044</Identifier><AffiliationInfo><Affiliation>Centre for Health Economics at Warwick, University of Warwick, Coventry, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belcher</LastName><ForeName>John</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-6844-0932</Identifier><AffiliationInfo><Affiliation>School of Medicine, Keele University, Keele, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fotheringham</LastName><ForeName>James</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8980-2223</Identifier><AffiliationInfo><Affiliation>School of Health and Related Research, University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sheffield Kidney Institute, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coyle</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-0441-2996</Identifier><AffiliationInfo><Affiliation>NIHR Devices for Dignity, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindley</LastName><ForeName>Elizabeth J</ForeName><Initials>EJ</Initials><Identifier Source="ORCID">0000-0003-4957-4489</Identifier><AffiliationInfo><Affiliation>Renal Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keane</LastName><ForeName>David F</ForeName><Initials>DF</Initials><Identifier Source="ORCID">0000-0002-4744-4106</Identifier><AffiliationInfo><Affiliation>CÚRAM SFI Research Centre for Medical Devices, University of Galway, Galway, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caskey</LastName><ForeName>Fergus J</ForeName><Initials>FJ</Initials><Identifier Source="ORCID">0000-0002-5199-3925</Identifier><AffiliationInfo><Affiliation>Population Health Sciences, University of Bristol, Bristol, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dasgupta</LastName><ForeName>Indranil</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-7448-2677</Identifier><AffiliationInfo><Affiliation>Renal Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Warwick Medical School, University of Warwick, Coventry, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davenport</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4467-6833</Identifier><AffiliationInfo><Affiliation>UCL Department of Renal Medicine, Royal Free Hampstead NHS Trust, University College, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrington</LastName><ForeName>Ken</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-8862-6056</Identifier><AffiliationInfo><Affiliation>Renal Medicine, East &amp; North Hertfordshire NHS Trust, Hertfordshire, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitra</LastName><ForeName>Sandip</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0389-636X</Identifier><AffiliationInfo><Affiliation>Manchester Academic Health Sciences Centre (MAHSC), Manchester University Hospitals and University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ormandy</LastName><ForeName>Paula</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-6951-972X</Identifier><AffiliationInfo><Affiliation>School of Health and Society, University of Salford, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilkie</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1059-6453</Identifier><AffiliationInfo><Affiliation>Sheffield Kidney Institute, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macdonald</LastName><ForeName>Jamie H</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0002-2375-146X</Identifier><AffiliationInfo><Affiliation>Institute for Applied Human Physiology, Bangor University, Bangor, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solis-Trapala</LastName><ForeName>Ivonne</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-1264-1396</Identifier><AffiliationInfo><Affiliation>School of Medicine, Keele University, Keele, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sim</LastName><ForeName>Julius</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-1816-1676</Identifier><AffiliationInfo><Affiliation>School of Medicine, Keele University, Keele, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Simon J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0001-5127-4755</Identifier><AffiliationInfo><Affiliation>School of Medicine, Keele University, Keele, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andronis</LastName><ForeName>Lazaros</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-7998-7431</Identifier><AffiliationInfo><Affiliation>Centre for Health Economics at Warwick, University of Warwick, Coventry, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Health Technol Assess</MedlineTA><NlmUniqueID>9706284</NlmUniqueID><ISSNLinking>1366-5278</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>‘Bioimpedance’ is a measure of how difficult it is for an electric current to pass through a biological object. Bioimpedance is used in devices that assess fluid status (over- or under-hydration) because it is very sensitive to the amount of water in tissue. Bioimpedance can be used in addition to clinical judgement when deciding how much water should be removed from someone with kidney failure during a dialysis treatment session. This is the first study to examine whether using this treatment represents a cost-effective use of National Health Service resources. We carried out an economic evaluation within a large randomised controlled trial in patients with kidney disease undergoing haemodialysis. We calculated the additional costs and quality-adjusted life-years (a measure that combines quality and quantity of life) using established methods. Over 2 years, our study showed that taking into account bioimpedance measurements about target weight resulted in slightly lower costs and marginally more quality-adjusted life-years, although there is uncertainty around these findings.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BIOIMPEDANCE</Keyword><Keyword MajorTopicYN="N">COST–UTILITY ANALYSIS</Keyword><Keyword MajorTopicYN="N">FLUID MANAGEMENT</Keyword><Keyword MajorTopicYN="N">HAEMODIALYSIS</Keyword><Keyword MajorTopicYN="N">RANDOMISED CONTROLLED TRIAL</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>11</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39325432</ArticleId><ArticleId IdType="doi">10.3310/JYPR4287</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bargman JM, Thorpe KE, Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol: JASN 2001;12:2158–62.</Citation></Reference><Reference><Citation>Termorshuizen F, Dekker FW, van Manen JG, Korevaar JC, Boeschoten EW, Krediet RT; NECOSAD Study Group. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol: JASN 2004;15:1061–70.</Citation></Reference><Reference><Citation>Obi Y, Rhee CM, Mathew AT, Shah G, Streja E, Brunelli SM, et al. Residual kidney function decline and mortality in incident hemodialysis patients. J Am Soc Nephrol: JASN 2016;27:3758–68.</Citation></Reference><Reference><Citation>Merkus MP, Jager KJ, Dekker FW, Boeschoten EW, Stevens P, Krediet RT. Quality of life in patients on chronic dialysis: self-assessment 3 months after the start of treatment. Am J Kidney Dis: Off J Nat Kidney Found 1997;29:584–92.</Citation></Reference><Reference><Citation>Schiffl H, Lang SM, Fischer R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol Dial Transp: Off Eur Dial Transp Assoc: Eur Renal Assoc 2002;17:1814–8.</Citation></Reference><Reference><Citation>Lu W, Ren C, Han X, Yang X, Cao Y, Huang B. The protective effect of different dialysis types on residual renal function in patients with maintenance hemodialysis: a systematic review and meta-analysis. Medicine 2018;97:e12325.</Citation></Reference><Reference><Citation>Lang SM, Bergner A, Töpfer M, Schiffl H. Preservation of residual renal function in dialysis patients: effects of dialysis-technique–related factors. Perit Dial Int: J Int Soc Perit Dial 2001;21:52–7.</Citation></Reference><Reference><Citation>Dasgupta I, Farrington K, Davies SJ, Davenport A, Mitra S. UK National Survey of practice patterns of fluid volume management in haemodialysis patients: a need for evidence. Blood Purif 2016;41:324–31.</Citation></Reference><Reference><Citation>Renal Registry. Chapter 3: Adults on Renal Replacement Therapy (RRT) in the UK at the End of 2019. In: UK Kidney Association. UK Renal Registry 23rd Annual Report; data to 31/12/2019. Bristol: UK Kidney Association; 2020. URL: https://ukkidney.org/sites/renal.org/files/23rd_UKRR_ANNUAL_REPORT_PREV_Ch3.pdf (accessed 3 June 2023).</Citation></Reference><Reference><Citation>Kidney Research UK. Kidney Disease: A UK Public Health Emergency. The Health Economics of Kidney Disease to 2033. Peterborough: Kidney Research UK; 2023. URL: www.kidneyresearchuk.org/wp-content/uploads/2023/06/Economics-of-Kidney-Disease-full-report_accessible.pdf (accessed 12 February 2023).</Citation></Reference><Reference><Citation>Tabinor M, Elphick E, Dudson M, Kwok CS, Lambie M, Davies SJ. Bioimpedance-defined overhydration predicts survival in end stage kidney failure (ESKF): systematic review and subgroup meta-analysis. Sci Rep 2018;8:1–14.</Citation></Reference><Reference><Citation>Dekker M, Marcelli D, Canaud B, Konings C, Leunissen K, Levin N, et al. Unraveling the relationship between mortality, hyponatremia, inflammation and malnutrition in hemodialysis patients: results from the international MONDO initiative. Eur J Clin Nutr 2016;70:779–84.</Citation></Reference><Reference><Citation>Hecking M, Moissl U, Genser B, Rayner H, Dasgupta I, Stuard S, et al. Greater fluid overload and lower interdialytic weight gain are independently associated with mortality in a large international hemodialysis population. Nephrol Dial Transp: Off Eur Dial Transp Assoc: Eur Renal Assoc 2018;33:1832–42.</Citation></Reference><Reference><Citation>Zoccali C, Moissl U, Chazot C, Mallamaci F, Tripepi G, Arkossy O, et al. Chronic fluid overload and mortality in ESRD. J Am Soc Nephrol: JASN 2017;28:2491–7.</Citation></Reference><Reference><Citation>National Institute for Health and Care Research. BioImpedance Spectroscopy to Maintain Renal Output: The BISTRO Trial. Research Award, Award ID: 14/216/01. 2021. URL: https://fundingawards.nihr.ac.uk/award/14/216/01 (accessed 12 March 2024).</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence. Chronic Kidney Disease in Adults. Quality Standard QS5. London: NICE; 2017. URL: www.nice.org.uk/guidance/qs5 (accessed 16 January 2023).</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence. Renal Replacement Therapy Services for Adults. NICE Quality Standard 72. London: NICE; 2018. URL: www.nice.org.uk/guidance/qs72 (accessed 25 January 2023).</Citation></Reference><Reference><Citation>Greene J, Hibbard JH. Why does patient activation matter? An examination of the relationships between patient activation and health-related outcomes. J Gen Intern Med 2012;27:520–6.</Citation></Reference><Reference><Citation>Hibbard J, Gilburt H. Supporting People to Manage Their Health: An Introduction to Patient Activation. London: King’s Fund; 2014.</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence. Multiple Frequency Bioimpedance Devices to Guide Fluid Management in People with Chronic Kidney Disease Having Dialysis. Diagnostics Guidance DG29. London: NICE; 2017. URL: www.nice.org.uk/guidance/dg29 (accessed 23 May 2024).</Citation></Reference><Reference><Citation>Davies SJ, Coyle D, Lindley EJ, Keane D, Belcher J, Caskey FJ, et al. Bio-impedance spectroscopy added to a fluid management protocol does not improve preservation of residual kidney function in incident hemodialysis patients in a randomized controlled trial. Kidney Int 2023;104:587–98.</Citation></Reference><Reference><Citation>Davies SJ, Caskey FJ, Coyle D, Lindley E, Macdonald J, Mitra S, et al. Rationale and design of BISTRO: a randomized controlled trial to determine whether bioimpedance spectroscopy-guided fluid management maintains residual kidney function in incident haemodialysis patients. BMC Nephrol 2017;18:1–11.</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal 2013. London: NICE; 2013. URL: www.nice.org.uk/process/pmg9/chapter/foreword (accessed 5 December 2022).</Citation></Reference><Reference><Citation>Scotland G, Cruickshank M, Jacobsen E, Cooper D, Fraser C, Shimonovich M, et al. Multiple-frequency bioimpedance devices for fluid management in people with chronic kidney disease receiving dialysis: a systematic review and economic evaluation. Health Technol Assess 2018;22:1–138.</Citation></Reference><Reference><Citation>Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727–36.</Citation></Reference><Reference><Citation>Ware JE Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;220:33.</Citation></Reference><Reference><Citation>Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ 2018;27:7–22.</Citation></Reference><Reference><Citation>Sampson C. Bad reasons not to use the EQ-5D-5L. aheblog: The Academic Health Economists’ Blog 23 March 2018. URL: https://aheblog.com/2018/03/23/bad-reasons-not-to-use-the-eq-5d-5l (accessed 11 October 2022).</Citation></Reference><Reference><Citation>NICE. Position Statement on Use of the EQ-5D-5L Value Set for England (updated October 2019). URL: www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l (accessed 23 May 2022).</Citation></Reference><Reference><Citation>Hernandez Alava M, Pudney S, Wailoo AJP. Estimating the relationship between EQ-5D-5L and EQ-5D-3L: results from a UK population study. PharmacoEcon 2023;41:199–207.</Citation></Reference><Reference><Citation>Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care 2004;42:851–9.</Citation></Reference><Reference><Citation>Billingham L, Abrams KR, Jones DR. Methods for the analysis of quality-of-life and survival data in health technology assessment. Health Technol Assess 1999;3:1–152.</Citation></Reference><Reference><Citation>Personal Social Services Research Unit. Client Service Receipt Inventory (CSRI). Canterbury: University of Kent; 2019. URL: www.pssru.ac.uk/csri/client-service-receipt-inventory (accessed July 2022).</Citation></Reference><Reference><Citation>Curtis L, Burns A. Unit Costs of Health and Social Care 2020, Personal Social Services Research Unit (PSSRU). Canterbury: University of Kent; 2020. URL: www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2020 (accessed 6 May 2022).</Citation></Reference><Reference><Citation>NHS England. National Schedule of NHS Costs: All NHS Trusts and NHS foundation trusts: HRG Data 2019/20. URL: www.england.nhs.uk/publication/2019-20-national-cost-collection-data-publication (accessed 27 March 2022).</Citation></Reference><Reference><Citation>NHS England. HRG4 + 2020/21 National Costs Grouper. URL: https://digital.nhs.uk/services/national-casemix-office/downloads-groupers-and-tools/hrg4-2020-21-national-costs-grouper (accessed 21 April 2022).</Citation></Reference><Reference><Citation>NHS England. NHS Data Model and Dictionary: Point of Delivery Code (Patient Level Information Costing) 2021. URL: https://datadictionary.nhs.uk/data_elements/point_of_delivery_code__patient_level_information_costing_.html (accessed 5 February 2023).</Citation></Reference><Reference><Citation>Department of Health. Reference Costs Guidance 2015–16. London: Department of Health; 2016. URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/497127/Reference_costs_guidance_2015-16.pdf (accessed 8 January 2023).</Citation></Reference><Reference><Citation>Posnett J, Jan S. Indirect cost in economic evaluation: the opportunity cost of unpaid inputs. Health Econ 1996;5:13–23.</Citation></Reference><Reference><Citation>Rubin DB. Statistical matching using file concatenation with adjusted weights and multiple imputations. J Bus Econ Stat 1986;4:87–94.</Citation></Reference><Reference><Citation>Faria R, Gomes M, Epstein D, White I. A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. PharmacoEcon 2014;32:1157–70.</Citation></Reference><Reference><Citation>Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA task force report. Value Health: J Int Soc Pharmacoecon Outc Res 2005;8:521–33.</Citation></Reference><Reference><Citation>Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 2000;19:3219–36.</Citation></Reference><Reference><Citation>Lee Y, Nelder JA. Hierarchical generalised linear models: a synthesis of generalised linear models, random‐effect models and structured dispersions. Biometrika 2001;88:987–1006.</Citation></Reference><Reference><Citation>Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press; 2015.</Citation></Reference><Reference><Citation>Glick HA, Jalpa DA, Sonnad SS, Polsky D. Economic Evaluation in Clinical Trials. Oxford: Oxford University Press; 2007.</Citation></Reference><Reference><Citation>Barton GR, Briggs AH, Fenwick EA. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Health 2008;11:886–97.</Citation></Reference><Reference><Citation>Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al.; ISPOR Health Economic Evaluation Publication Guidelines – CHEERS Good Reporting Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS): explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health 2013;16:231–50.</Citation></Reference><Reference><Citation>Wright C, Sim J. Intention-to-treat approach to data from randomized controlled trials: a sensitivity analysis. J Clin Epidemiol 2003;56:833–42.</Citation></Reference><Reference><Citation>Claxton KJJ. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999;18:341–64.</Citation></Reference><Reference><Citation>Ramsey SD, Willke RJ, Glick H, Reed SD, Augustovski F, Jonsson B, et al. Cost-effectiveness analysis alongside clinical trials II – an ISPOR Good Research Practices Task Force report. Value Health 2015;18:161–72.</Citation></Reference><Reference><Citation>UK Kidney Association. Renal Units. URL: https://units.renal.org/index.pl?qp=1 (accessed 22 May 2022).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>